# EVALUATION OF CONTEMPORARY OXYGENATOR PERFORMANCE

ROGER STANZEL

CPC, PHD, ADJUNCT PROFESSOR OF MEDICINE, DALHOUSIE UNIVERSITY

MARK HENDERSON

CPC, CCP

BILL O'REILLY

CPC, CCP





Caring for You. Innovating for the World.®



- BACKGROUND/GOALS
- BENCH-TOP ANALYSIS
  - GME
- <u>CLINICAL ANALYSIS</u>
  - MULTICENTER EVALUATION OF CONTEMPORARY OXYGENATORS
  - POST-HOC ANALYSIS



### BACKGROUND

- CARDIAC SURGERY IS COMPLEX
- OUTCOMES ARE THE SUM OF A LARGE NUMBER OF COMPONENTS, BUT GENERALLY SAFE...
  - <u>WHY?</u>
    - MANY TECHNOLOGICAL ADVANCEMENTS IN CARDIAC SURGERY
      - SURGICAL/ANESTHETIC PRACTICE
      - PERFUSION PRACTICE/EQUIPMENT
        - INCREASED BIOCOMPATIBILITY: CIRCUIT COATINGS, REDUCED SURFACE AREA
        - REDUCED PRIME: INTEGRATED ARTERIAL FILTERS, SMALLER OXYGENATORS



 QUALITY ASSURANCE INITIATIVE TO IDENTIFY THE BEST OXYGENATOR FOR OUR CARDIAC SURGERY PATIENTS

- <u>HOW:</u>
  - BENCH-TOP AND CLINICAL EVALUATIONS



### SOURCE MATERIAL

- CLINICAL EVALUATION OF CONTEMPORARY OXYGENATORS", STANZEL AND HENDERSON, PERFUSION 2015
- "AN IN VITRO EVALUATION OF GASEOUS MICROEMBOLI HANDLING BY CONTEMPORARY VENOUS RESERVOIRS AND OXYGENATOR SYSTEMS USING EDAC", STANZEL AND HENDERSON, PERFUSION 2015
- "IS THERE A RELATIONSHIP BETWEEN PRESSURE GRADIENTS THROUGH CONTEMPORARY OXYGENATORS AND IMMUNE CELL PROLIFERATION DURING
  CARDIOPULMONARY BYPASS? A PILOT STUDY", STANZEL AND HENDERSON, JECT, 2017.
- **"A CLINICAL EVALUATION OF CONTEMPORARY OXYGENATORS: A MULTI-CENTRE EVALUATION"**, STANZEL, HENDERSON AND O'REILLY. IN PREPARATION FOR SUBMISSION.



- BACKGROUND/GOALS
- <u>BENCH-TOP ANALYSIS</u>
  - GME
- <u>CLINICAL ANALYSIS</u>
  - MULTICENTER EVALUATION OF CONTEMPORARY OXYGENATORS
  - POST-HOC ANALYSIS



#### HARMS OF GASEOUS MICRO EMBOLI

- CPB GENERATES GME
  - CAN OBSTRUCT END-ORGAN PERFUSION
- CEREBRAL ISCHEMIA?
  - POST OPERATIVE DYSFUNCTION, TRANSIENT TO PERMANENT
- GOALS:
  - IDENTIFY OPTIMUM CPB PRODUCTS TO PROTECT PATIENTS FROM GME:
    - VENOUS RESERVOIR
    - OXYGENATOR
    - SYSTEM
- <u>EMBOLI DETECTION AND CLASSIFICATION (EDAC<sup>™</sup>)</u>:
  - EVALUATE VARIOUS SIZES OF GME
  - EVALUATE OVERALL GME LOAD



#### PRODUCTS:

- SORIN SYNTHESIS
- SORIN INSPIRE (6 AND 8)
- TERUMO FX (15 AND 25)
- MAQUET QUADROX-I

#### • PARAMETERS:

- <u>BLOOD</u>:
  - BOVINE
    - 15 L
    - HCT 30 ± 2
    - BE 0 ± 2
    - PH 7.1 7.3

#### • OXYGENATOR SET UP:

- FLUSHED (3 LPM CO<sub>2</sub> FOR 5 MIN) AND PRIMED AS PER MANUFACTURERS' INSTRUCTIONS
- 4 LPM FLOW
- VENOUS RESERVOIR AT MINIMUM
  OPERATING VOLUME
- RUN AS PER MANUFACTURERS'
  INSTRUCTIONS
- AIR INTRODUCTION:
  - 30 SECONDS BASELINE
  - 1 MINUTE OF ROOM AIR (100 CC OVER 1 MINUTE)
- AFTER COMPLETION:
  - CIRCUIT DE-AIRED PRIOR TO NEXT
    ANALYSIS
  - ONE OF EACH OXYGENATORS
    - 2 RUNS PER OXYGENATOR



#### • <u>SET-UP:</u>



#### <u>GME DETECTION</u>

- <u>CHANNEL 1:</u> DISTAL VENOUS RESERVOIR
- <u>CHANNEL 2:</u> DISTAL ARTERIAL ROLLER
  PUMP
- <u>CHANNEL 3:</u> DISTAL OXYGENATOR

#### • **PROCEDURE:**

- BASELINE GME ESTABLISHED (<10 EMBOLI/6 SECONDS)
- <u>AIR INJECTION</u>
  - 100 CC ROOM AIR OVER 1
    MINUTE THROUGH
    STOPCOCK IN VENOUS
    LINE
- GME DATA RECORDED DURING AIR
  INJECTION THEN FOLLOWING 3 MINUTES



#### Reservoir:





#### **Oxygenator:**





#### Total System:





#### <u>CONCLUSIONS:</u>

- VARYING ABILITY TO REMOVE GME
  - <u>RESERVOIR:</u> MAQUET SUPERIOR
  - OXYGENATOR: COMPARABLE, EXCEPT MAQUET WITH 100 MM+ GME
  - <u>SYSTEM</u>: SYNTHESIS INFERIOR
- NEWER TECHNOLOGY HAS IMPROVED GME HANDLING



- BACKGROUND/GOALS
- BENCH-TOP ANALYSIS
  - GME
- <u>CLINICAL ANALYSIS</u>
  - MULTICENTER EVALUATION OF CONTEMPORARY OXYGENATORS
  - POST-HOC ANALYSIS



- IN 2015, HALIFAX CONDUCTED SMALL CLINICAL EVALUATION OF CURRENT OXYGENATOR AND NEW OXYGENATORS
- <u>METRICS</u>
  - PRIME
  - GAS EXCHANGE
  - PRESSURE GRADIENTS
  - EFFECTS ON BLOOD ELEMENTS
- SIGNIFICANT DIFFERENCES
- ARE THESE REPRODUCIBLE?
  - SMALL MULTICENTRE EVALUATION USING THE SAME PROTOCOL
    - <u>HYPOTHESIS</u>:
      - DATA FROM OTHER CENTERS AGREE WITH INITIAL EVALUATION



### MULTICENTER CLINICAL EVALUATION

#### PARTICIPATING CENTERS: ٠

- HALIFAX
- NEW BRUNSWICK
- LONDON

#### OXYGENATORS:

- FX25
- INSPIRE-8
- QUADROX-I
- N = 100

#### • **STATISTICS**

- CATEGORICAL DATA
  - FISCHER'S EXACT TEST
- QUANTITATIVE DATA
  - ANOVA WITH BONFERRONI CORRECTION

MEMBRAN	IE OXYGENA	TOR AU	JDIT		MEMBRANE:		
Research C				PERFUSIONIST:			
Pt Study No			]	SURGEON/ANES:			
				•	PUMP TIME:		
					XC TIME		
					PROCEDURE:		
TIME	SAMPLE:	RBC	WBC	Neut	PLT	HGB	HCT
	PRE CPB:						
	XC REMOVAL:						

NE:			
IONIST:			
N/ANES:			Main Pu
ME:			TRANSF
URE:			Ht
	HGB	HCT	Wt
			BSA
			GENDER

Main Pump type	
TRANSFUSED BLOOD	(UNITS

Pt Sticker
------------

		Blood Analyzer		Device		Blood Analyzer			Device								
		Arterial O <sub>2</sub> Content		Arterial		Venous O <sub>2</sub> Content			Venous		CO <sub>2</sub> Transfer			Pressure			
ON CPB	ART TEMP	HgB	SaO <sub>2</sub>	PaO <sub>2</sub>	HgB	8a0 <sub>2</sub>	8vO <sub>2</sub>	HgB	PvO <sub>2</sub>	HgB	SvO <sub>2</sub>	BLOOD FLOW	PaCO <sub>2</sub>	GAS FLOW	FIO <sub>2</sub>	PRE	POST
SAMPLE 1																	
SAMPLE 2																	
SAMPLE 3																	
SAMPLE 4																	
SAMPLE 5																	
SAMPLE 6																	
SAMPLE 7																	
SAMPLE 8																	

AGE



NO DIFFERENCES IN PATIENT OR CASE DEMOGRAPHICS







O<sub>2</sub> Transfer as a Function of FiO<sub>2</sub>

Inspire\_1 had lowest O<sub>2</sub> transfer (except FX25)





Inspire\_2 required lower gas flow than Quadrox\_1 to achieve 40 mmHg PaCO<sub>2</sub>





Inspire > FX25 > Quadrox

### **HEMATOLOGY**

- <u>CORE LABORATORY SERVICES (QEII)</u>
- <u>SAMPLES</u>:
  - POST-HEPARIN, PRE-CPB (BASELINE)
  - POST-CROSS CLAMP
- PARAMETERS:
  - HEMOGLOBIN, PLATELETS, WHITE BLOOD CELLS
- EVALUATION:
  - NORMALIZED TO 'POST-HEPARIN' VALUE
    - % BASELINE







### MULTICENTER CLINICAL EVALUATION



**HgB Post Cross Clamp** 



Inspire\_1 < FX25\_1





FX25\_1 had greatest Plt retention









#### <u>CONCLUSIONS</u>

#### OBSERVED UNEXPECTED DIFFERENCES TO INITIAL EVALUATION

- GAS EXCHANGE
- HGB
- PLT
- WBC

#### • <u>WHX</u>5

- DIFFERENCES IN CLINICAL PRACTICE?
- WHAT ARE THEY ...?



- BACKGROUND/GOALS
- BENCH-TOP ANALYSIS
  - GME
- <u>CLINICAL ANALYSIS</u>
  - MULTICENTER EVALUATION OF CONTEMPORARY OXYGENATORS
  - POST-HOC ANALYSIS



 $\tau$  > 75 dynes/cm<sup>2</sup>: Leukocytes

Sublytic granule release, adhesion, aggregation and phagocytosis

• SHEAR STRESS IN AN OXYGENATOR (T) =  $\{(\eta \times Q_{blood} \times \Delta P)/(V_{prime})\}$ 

<u>Where:</u> η = absolute viscosity

 $Q_{blood}$  = blood flow

 $\Delta P$  = pressure drop

V<sub>prime</sub> = prime volume



#### $\tau$ > 75 dynes/cm<sup>2</sup>: Leukocytes

Sublytic granule release, adhesion, aggregation and phagocytosis





#### $\tau$ > 75 dynes/cm<sup>2</sup>: Leukocytes

Sublytic granule release, adhesion, aggregation and phagocytosis



*High pressure-drop oxygenators may be pro-inflammatory?* 





## C

### **UNDER PRESSURE?**





- NO CORRELATION BETWEEN PRESSURE AND IMMUNE CELL PROLIFERATION ON CPB
- <u>CONCLUSION:</u>

• S

- OTHER FACTORS RESPONSIBLE
- COATINGS
- OXYGENATOR DESIGN



### CONCLUSIONS

- MODERN TECHNOLOGY HAVE IMPROVED GME REMOVAL
- DIFFERENCES IN CLINICAL PERFORMANCE
- GAS EXCHANGE, CBC
- PRESSURE DROP NOT RESPONSIBLE FOR DIFFERENCES IN IMMUNE CELL INCREASES



### FUTURE GOALS

- ANSWER THE QUESTION: WHY THE DIFFERENCES IN CLINICAL PERFORMANCE?
  - INCREASING NUMBER OF PARTICIPATING CENTERS
- ONGOING QUALITY ASSURANCE
  - TRACK OXYGENATOR PERFORMANCE
  - ESTABLISH A BASELINE AND ASSESS IMPACTS OF CHANGE IN PRACTICE
- RE-INVIGORATE INTEREST IN PERFUSION RESEARCH



### THANK YOU

- CSCP CMOC
- BILL HILL, LANCE MITCHELL AND NSHA PERFUSION STAFF
- CHRIS MACKAY AND LHSC PERFUSION STAFF
- HNH PERFUSION STAFF